Carregant...
Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma
Ipilimumab is an anti-CTLA-4 antibody that is approved for the treatment of metastatic malignant melanoma. Side-effects are mostly immune-mediated and in many cases the lack of specific symptoms leads to delayed diagnosis and treatment of adverse events. We present the case of a female patient who e...
Guardat en:
| Publicat a: | Dermatoendocrinol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4977105/ https://ncbi.nlm.nih.gov/pubmed/27574531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19381980.2016.1199307 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|